cft

Human Growth Hormone HGH Market to Grow $8.67 Billion by 2029

Human Growth Hormone hGH: by Application (Growth Hormone Deficiency, Prader-Willi Syndrome, Turner Syndrome, Small for Gestational Age, and Others); by Route of Administration (Intravenous, Intramuscular, Subcutaneous, and Oral); by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, and Online Pharmacy); by Region (North America, Europe, Asia Pacific, Latin America and Middle East, and Africa) Global Industry Analysis, COVID-19 Impact, and Industry Forecast, 2017-2029


user

CMR Sales

14 days ago | 4 min read


As per Cognitive Market Research analysis, HUMAN GROWTH HORMONE (HGH) market size is projected to grow from USD 3.88 Billion in year 2022 to USD 8.67 Billion by 2029 at a CAGR of 6.69% from 2022-2029.

Human Growth Hormone hGH Market Overview:

HGH is a substance produced by pituitary gland, which spurs growth among children and adolescents. It also helps to regulate body composition, body fluids, muscle and bone growth. Besides, it allows proper regulation of sugar and fat metabolism and to some extent heart function as well. Synthetically produced hGH has been developed in 1985 and approved by FDA strictly for specific uses.

Market Dynamics:

Surge in the prevalence of growth disorder in children:

Growth disorder refers to constitutional delay of growth and pubertal development. A child tends to be shorter than average and to enter puberty later than average, while growing at a normal rate. It is mainly affected because of disrupted hormones. It may be the result of injuries to the pituitary gland or brain. Cushing syndrome can impair height but cause weight gain. Precocious puberty is a condition caused by hormone problems. Owing to various factors, short stature is a common paediatric problem. According to WHO, 149 million children under 5 were estimated to be stunted in year 2020.

Children with growth hormone deficiency have abnormality in the natural process of pituitary gland. This results in lack of hGH production in body. In such conditions, synthetic human growth hormone is injected to stave off some of the changes linked to aging, such as decreased muscle and bone mass. Hence, surge in the prevalence of growth disorder in children propel the growth of hGH market.

Moreover, vigorous product pipeline and active R&D activities for the development of novel growth hormone therapies are expected to be the major factors driving the market for human growth hormones.

For instance, Ascendis Pharma has TransCon hGH in clinical trial process for paediatric and adult growth hormone deficiency in Japan, China and other parts of world. Thus, surging R&D activities will create lucrative opportunities in the growth of hGH market.

Top players involved in the Human Growth Hormone hGH market:

Majority of global manufacturers of Human Growth Hormone hGH are demonstrating world-class sustainable practices and are attracting a lot of capital.

  • Novo Nordisk
  • Anhui Anke Biotechnology (Group) Co., Ltd.
  • Genentech
  • Pfizer
  • Eli Lilly
  • Sandoz
  • TEVA PHARMACEUTICAL
  • Merck & Co.
  • Roche
  • Ipsen
  • Ferring BV
  • Others

News Section:

  • November 2022:

Lumos' oral growth hormone drug falls short of Novo's injectable incumbent at interim analysis

Texas-based Lumos is developing the drug candidate LUM-201, a small molecule that Merck previously studied in patients with growth hormone deficiency, in the belief it promotes secretion of the hormone from the pituitary gland. However, the oral treatment of Lumos Pharma has failed to match up to Novo Nordisk’s injected drug Norditropin at the interim analysis of a phase 2 trial. But with growth in the Norditropin arm exceeding expectations, Lumos has pinned the blame on baseline imbalances.

  • September 2019:

Novo Nordisk’s somapacitan shows favourable profile in GHD trial

The company has reported positive data from the Phase II REAL 3 clinical trial of somapacitan in children with growth hormone deficiency (GHD). The drug has demonstrated safety, efficacy and tolerability comparable to that of once-daily Norditropin (somatropin) after one year. An improved efficacy has been reported for the highest somapacitan dose.

  • May 2016:

Genentech has received approval for hGH in USA:

Genentech has received approval to market its recombinant human growth hormone product, Nutropin, for the treatment of short stature caused by GH deficiency in the USA. The approval came on the same day that Eli Lilly's period of orphan drug exclusivity for its Humatrope (somatropin) product ran out.

Nutropin was Genentech's second hGH product in the market - its Protropin version, first launched in 1985, is slightly different in structure.

  • January 2022:

FDA snubs new growth deficiency med somatrogon, developed by Pfizer and partner OPKO Health:

The FDA has rejected somatrogon, a potential treatment for pediatric growth hormone deficiency. Pfizer lost a first-mover advantage for a long-acting pediatric growth hormone deficiency drug in the U.S. when Ascendis Pharma won an FDA go-ahead in August for Skytrofa, which is also given once every week.

Segment Analysis:

  • By Application:

Growth Hormone Deficiency dominates the market of hGH in 2021:

Synthetic human growth hormone was developed in 1985, but FDA approved the usage of drug only for specific disorders. For instance, it is commonly used in children for treating short stature of unknown cause as well as poor growth due to a number of medical causes.

Further, awareness regarding turner syndrome is rising and thus hGH use in this syndrome is creating opportunities for the growth of market.

For detailed segment analysis: click here: https://www.cognitivemarketresearch.com/human-growth-hormone-hgh-market-report

Top Report Findings:

  • North America is predicted to make up the greatest portion of the market due to excellent reimbursement conditions
  • Asia-Pacific is expected to register the highest CAGR in terms of revenue during the forecast period
  • hGH is widely given intramuscular route of administration
  • Surge in the prevalence of growth disorder in children propel the growth of hGH market

Conclusion:

Besides, report covers complete manufacturers analysis. Additionally, it provides sales channel, analysis findings and results. The report covers holistic analysis on external and internal factors affecting the growth of market. It spots some new entrants within the market. The study thus, suggests a brand-new proposition to embellish Human Growth Hormone hGH market and nurture business as it explains current global market as well as future market.

Related Report:

About Cognitive Market Research Company:

Our company gather and analyze data about customers, competitors, distributors, and other actors and forces in the marketplace. We being a market research company, follows a complete process of gathering information about target market and end-use industries to verify complete journey of the product in the global market. It helps our readers to understand the demand and viability of their product/service and to see how it might perform in the real world.

The global market also includes analysing the global, regional, and country levels, along with key market trends, significant players analysis, market growth strategies, and key application areas.

Report is a complete blend about consumer behaviour and economic trends to confirm and improve business strategies. We additionally accept customization of report as per client requirements in order to provide more insightful content to readers.

  • 24/7 free analyst availability
  • Free pre-sale and post-sale support
  • Additional country analysis/manufacturers analysis
  • Quarterly updates

Contact Us

Nicolas Shaw

sales@cognitivemarketresearch.com

Call Us On

  • USA: +1 312-376-8303
  • Europe and UK: (+44) 20-8144-9523
  • Asia Pacific: (+852) 81930785

Upvote


user
Created by

CMR Sales


people
Post

Upvote

Downvote

Comment

Bookmark

Share


Related Articles